Drug Trial Radar · NCT06843590
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia
Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
126
Planned (sponsor's estimate)
Start
May 22, 2025
Primary completion
Nov 2026
Study completion Nov 2026
Sponsor
- Lead sponsor
- Alkermes, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to measure the safety and decrease in daytime sleepiness in subjects with Idiopathic Hypersomnia when taking ALKS 2680 tablets compared with placebo tablets
Conditions
- Idiopathic Hypersomnia
Interventions
ALKS 2680Drug
Oral tablet containing ALKS 2680 for daily, oral administration
PlaceboDrug
Oral placebo tablet for daily administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Epworth Sleepiness Scale (ESS) from baseline to Week 8 by dose levelTime frame: Up to 8 weeks
Locations
50 sites in 8 countries. Site status is shown where the registry gives one.
Alkermes Investigator Site
Cullman, Alabama
Alkermes Investigator Site
Phoenix, Arizona
Alkermes Investigator Site
Little Rock, Arkansas
Alkermes Investigator Site
Los Angeles, California
Alkermes Investigator Site
Redwood City, California
Alkermes Investigator Site
San Francisco, California
Alkermes Investigational Site
Boulder, Colorado
Alkermes Investigator Site
Colorado Springs, Colorado
Alkermes Investigator Site
Brandon, Florida
Alkermes Investigator Site
Miami, Florida
Alkermes Investigator Site
Winter Park, Florida
Alkermes Investigator Site
Atlanta, Georgia
Alkermes Investigator Site
Macon, Georgia
Alkermes Investigator Site
Stockbridge, Georgia
Alkermes Investigator Site
Peoria, Illinois
Alkermes Investigator Site
Kansas City, Kansas
Alkermes Investigational Site
Boston, Massachusetts
Alkermes Investigator Site
Lansing, Michigan
Alkermes Investigator Site
Lincoln, Nebraska
Alkermes Investigator Site
Middletown, New Jersey
Alkermes Investigator Site
Denver, North Carolina
Alkermes Investigator Site
Huntersville, North Carolina
Alkermes Investigator Site
Canton, Ohio
Alkermes Investigator Site
Cincinnati, Ohio
Alkermes Investigator Site
Cleveland, Ohio
Alkermes Investigator Site
Danville, Pennsylvania
Alkermes Investigator Site
Philadelphia, Pennsylvania
Alkermes Investigator Site
Wyomissing, Pennsylvania
Alkermes Investigator Site
Columbia, South Carolina
Alkermes Investigator Site
Austin, Texas
Alkermes Investigator Site
San Antonio, Texas
Alkermes Investigator Site
Sugar Land, Texas
Alkermes Investigator Site
Sugarland, Texas
Alkermes Investigator Site
Madison, Wisconsin
Alkermes Investigator Site
Sydney, New South Wales, Australia
Alkermes Investigator Site
Bedford Park, South Australia, Australia
Alkermes Investigator Site
Clayton, Victoria, Australia
Alkermes Investigator Site
Alken, Belgium
Alkermes Investigator Site
Namur, Belgium
Alkermes Investigator Site
Prague, Czechia
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.